Supreme Court Declines CareDx Appeal in Natera Ad Dispute
The U.S. Supreme Court has rejected CareDx's appeal in a false-advertising case brought by genetic testing rival Natera.
The U.S. Supreme Court has declined to hear an appeal from CareDx in a false-advertising lawsuit filed by Natera, Inc., leaving intact lower court rulings in the closely watched dispute between two competing players in the genetic and transplant diagnostics space. The high court's refusal to take up the case marks a significant procedural setback for CareDx, which had sought to challenge findings related to how it marketed its organ transplant monitoring products against Natera's rival offerings.
The underlying litigation centers on allegations that CareDx made misleading claims in its advertising—a dispute that carries meaningful commercial weight given how aggressively both companies compete for market share in the donor-derived cell-free DNA testing segment. False-advertising cases of this nature, pursued under the Lanham Act, can result in injunctions, corrective advertising requirements, and damages that materially reshape competitive dynamics in specialized medical markets.
Read more Johnson & Johnson Wins Talc Cancer Lawsuit Involving Three Women →
For Natera, the Supreme Court's refusal to intervene is a validation of its legal strategy and may strengthen its hand as the case proceeds or concludes at the lower court level. For CareDx, the denial forecloses what had been its most direct avenue for relief and forces the company to contend with whatever remedies the lower courts ultimately impose. Investors in both companies will be watching closely, as the outcome could influence how each firm positions its flagship testing products going forward.
The broader takeaway for the diagnostics industry is that courts have shown increasing willingness to scrutinize comparative advertising claims in high-stakes medical technology markets, where overstated efficacy or misleading competitive comparisons can distort physician decision-making and patient outcomes. The CareDx-Natera dispute is unlikely to be the last of its kind as competition in liquid biopsy and transplant monitoring intensifies.
Continue reading at Yahoo Finance.
